重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死的临床疗效

Comparison Research between Recombinant Tissue Plasminogen Activator Intravenous Thrombolytic Therapy and Conventional Antiplatelet Therapy for Acute Cerebral Infarction

目的探讨重组组织型纤溶酶原激活剂静脉溶栓治疗与常规抗血小板治疗急性脑梗死的疗效对比.方法 2012年1月至2015年2月期间,天津市西青医院120例急性脑梗死患者,根据随机数字法,将其分为对照组(常规抗血小板治疗)和观察组(重组组织型纤溶酶原激活剂静脉溶栓治疗),每组各60例,比较2组治疗的临床疗效,根据NIHSS评分标准及Barthel指数(BI),评估治疗前后2组神经功能缺损及日常生活能力改善情况.结果与对照组相比,观察组的治愈率及总有效率均明显增高,P<0.05;与对照组相比,观察组治疗后NIHSS评分明显降低,P<0.05;与对照组相比,观察组治疗后BI评分显著提高,P<0.05.结论重组组织型纤溶酶原激活剂静脉溶栓治疗明显提高急性脑梗死的临床疗效,显著改善患者的神经缺损功能及日常生活能力,值得临床推广.

Objective To compare the efficacy between recombinant tissue plasminogen activator intravenous thrombolytic therapy and conventional antiplatelet therapy for acute cerebral infarction. Methods 120 patients with acute cerebral infarction in Tianjin Xiqing hospital from Jan 2013 to Feb 2015 were randomly divided into the control group（conventional antiplatelet therapy） and the observation group（recombinant tissue plasminogen activator intravenous thrombolytic therapy） according to the random number method, 60 patients per group. The clinical efficacy, the improvement of nerve function defect and daily living ability on pre- and post-treatment in the two groups were compared according to the NIHSS score and Barthel index（BI）. Results Compared with the control group, the cure rate and total effective rate were significantly increased（P〈0.05）,NIHSS scores were obviously reduced on post-treatment（P〈0.05）, and BI scores were significantly increased on post-treatment in the observation group（P〈0.05）. Conclusion The recombinant tissue plasminogen activator intravenous thrombolytic therapy can significantly increase the clinical efficacy for acute cerebral infarction and improve the nerve function defect and daily living ability, which is worthy of clinical promotion.